Cataract prevalence and prevention in Europe: a literature review

Abstract

This literature review is aimed at the evaluation of the potential for cataract prevention in Europe. It was performed using Pub-MED with Mesh and free text terms. Studies included were: a) performed on a population of Caucasian origin at an age range of 40-95 years, b) cataract was clinically verified, c) drug record of prescriptions, their indication, a record of every diagnosis, dosage, and quantity of prescribed medicine were available, d) sample size >300, e) published between 1990 and 2009. The results of 29 articles were reviewed. Former (3.75 [2.26-6.21]) or current smoking (2.34 [1.07-5.15]), diabetes of duration >10 years (2.72 [1.72-4.28]), asthma or chronic bronchitis (2.04 [1.04-3.81]), and cardiovascular disease (1.96 [1.22-3.14]) increased the risk of cataract. Cataract was more common in patients taking chlorpromazine during >90 days with a dosage >300 mg, corticosteroids used >5 years (3.25 [1.39-7.58]) in a daily dose >1600 mg (1.69 [1.17-2.43]), a multivitamin/mineral formulation (2.00 [1.35-2.98]) or corticosteroids (2.12 [1.93-2.33]). Corticosteroid applied orally (3.25 [1.39-7.58]), parenteral (1.56 [1.34-1.82]) or inhalational (1.58 [1.46-1.71]) lead to cataract more frequently than those applied topically: nasal (1.33 [1.21-1.45]), ear (1.31 [1.19-1.45]), or skin (1.43 [1.36-1.50]). Outpatient cataract surgery was negatively associated with total cataract surgery costs, and chlorpromazine, corticosteroids, and multivitamin/mineral formation increase the risk of posterior sub-capsular cataract dependent on dose, treatment application, and duration. This review presented a comprehensive overview of specific and general cataract risk factors and an update on most recent experimental studies and randomized control trials directed at cataract prevention